Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) has a MoatMap StockRank of 41/100 based on Quality (54/100), Value (24/100), and Momentum (51/100) factor scores. The current signal is HOLD. Yantai Dongcheng Pharmaceutical faces domestic pricing headwinds from Chinese volume-based procurement (VBP) and lacks a global, un-copyable moat in its nuclear medicine division.
Yantai Dongcheng Pharmaceutical is a leading global supplier of heparin sodium API and a pioneer in China's high-barrier radiopharmaceutical market. The company has established a strong competitive moat in nuclear medicine, operating a network of radiopharmacies for PET and SPECT diagnostic tracers. This dual-core model combines stable API export revenues with high-margin, high-growth domestic clinical diagnostics.
| Price | $1.82 |
| Market Cap | $1.6B |
| P/E (TTM) | 50.16 |
| P/E (Forward) | 20.56 |
| Price/Book | 2.41 |
| Return on Equity | 3.2% |
| Return on Invested Capital | 4.6% |
| Debt/Equity | 15.89 |
| Gross Margin | 52.5% |
| Operating Margin | 14.2% |
| Revenue Growth | -8.8% |
| Dividend Yield | 0.6% |
| Free Cash Flow | $787K |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).